✦ LIBER ✦

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

✍ Scribed by Gelmon, K.A.

Book ID: 123031924
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 107 KB
Volume: 22
Category: Article
ISSN: 1043-321X
DOI: 10.1016/j.breastdis.2011.03.043

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral poly(ADP-ribose) polymerase inhibit

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

✍ Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffr 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 594 KB

Oral poly(ADP-ribose) polymerase inhibit

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

✍ M William Audeh; James Carmichael; Richard T Penson; Michael Friedlander; Bethan 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 268 KB

Somatic Mutations in BRCA1 and BRCA2 Cou

Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

✍ Hennessy, B. T. J.; Timms, K. M.; Carey, M. S.; Gutin, A.; Meyer, L. A.; Flake, 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 182 KB

Phase II, Open-Label, Randomized, Multic

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

✍ Kaye, S. B.; Lubinski, J.; Matulonis, U.; Ang, J. E.; Gourley, C.; Karlan, B. Y. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 165 KB

The poly(ADP-ribose) polymerase inhibito

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

✍ Sandhu, Shahneen K; Schelman, William R; Wilding, George; Moreno, Victor; Baird, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 435 KB

First in human trial of the poly(ADP)-ri

First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers

✍ R. Wenham; G. Wilding; R. Baird; L. Sun; C. Toniatti; M. Stroh; C. Carpenter; J. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 71 KB